Literature DB >> 21227466

Mast cells are not involved in the ischemia-reperfusion injury in perfused rat liver.

Toshishige Shibamoto1, Mikihiro Tsutsumi, Yuhichi Kuda, Chieko Ohmukai, Wei Zhang, Yasutaka Kurata.   

Abstract

BACKGROUND: It is reported that mast cells are involved in ischemia-reperfusion (I/R) injury of several organs such as intestine, heart, and brain in rats. However, the roles of mast cells are not known in rat hepatic I/R injury. We determined using genetically mast cell deficient (Ws/Ws) rats whether mast cells participate in the genesis of hepatic I/R injury.
METHODS: Isolated livers from male Ws/Ws rats (n = 6), their wild type +/+ rats (n = 6), and Sprague Dawely (SD) rats (n = 12) were perfused portally with diluted blood (Hct 8%) at a constant blood flow. Ischemia was induced at room temperature by occlusion of the inflow line of the portal vein for 1 h, followed by 1-h reperfusion in a recirculating manner. The pre- and post-sinusoidal resistances were determined by measuring the portal venous pressure (Ppv), hepatic venous pressure, blood flow and the sinusoidal pressure, which was assessed by the double occlusion pressure (Pdo). Liver injury was assessed by blood alanine aminotransferase (ALT) levels, bile flow rate and histology of the livers.
RESULTS: In the +/+ group, liver injury occurred after reperfusion; blood ALT levels increased from 19 ± 4 (SD) to 71 ± 18 and 135 ± 30 (IU/L) at 30 and 60 min, respectively, and bile flow decreased to 51% ± 6% of the baseline at 60 min after reperfusion. Histologic examination revealed marked hepatic degeneration. Similar changes were observed in the Ws/Ws rats and the SD rats (n = 6), and there were no significant differences in the variables among the Ws/Ws, +/+, and SD groups. In any ischemia groups, immediately after reperfusion, Ppv substantially, but Pdo only slightly, increased, followed by a return towards the baseline, indicating a predominant increase in pre-sinusoidal resistance over post-sinusoidal resistance. Liver weight significantly increased at 60 min after reperfusion. In the control SD rats without I/R (n = 6), no significant changes were observed in the variables.
CONCLUSIONS: I/R injury occurs in the absence of hepatic mast cells in the isolated perfused rat liver model of I/R injury.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21227466     DOI: 10.1016/j.jss.2010.11.900

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  5 in total

1.  Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(-/-) mice.

Authors:  Hannah Jones; Laura Hargrove; Lindsey Kennedy; Fanyin Meng; Allyson Graf-Eaton; Jennifer Owens; Gianfranco Alpini; Christopher Johnson; Francesca Bernuzzi; Jennifer Demieville; Sharon DeMorrow; Pietro Invernizzi; Heather Francis
Journal:  Hepatology       Date:  2016-07-30       Impact factor: 17.425

2.  Tumor Necrosis Factor-α: Life and Death of Hepatocytes During Liver Ischemia/Reperfusion Injury.

Authors:  Maureen Shuh; Humberto Bohorquez; George E Loss; Ari J Cohen
Journal:  Ochsner J       Date:  2013

Review 3.  The role of mast cells in ischemia and reperfusion injury.

Authors:  Mu-qing Yang; Yuan-yuan Ma; Jing Ding; Ji-yu Li
Journal:  Inflamm Res       Date:  2014-08-10       Impact factor: 4.575

4.  Cromoglycate, not ketotifen, ameliorated the injured effect of warm ischemia/reperfusion in rat liver: role of mast cell degranulation, oxidative stress, proinflammatory cytokine, and inducible nitric oxide synthase.

Authors:  Nagla A El-Shitany; Karema El-Desoky
Journal:  Drug Des Devel Ther       Date:  2015-09-16       Impact factor: 4.162

5.  Degranulation of gastrointestinal mast cells contributes to hepatic ischemia-reperfusion injury in mice.

Authors:  Zhigang He; Yue Li; Sunqiang Ma; Muqing Yang; Yuanyuan Ma; Cheng Ma; Jian Song; Tianyu Yu; Siqi Zhang; Jiyu Li
Journal:  Clin Sci (Lond)       Date:  2018-10-29       Impact factor: 6.124

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.